Autoimmune pancreatitis in the setting of Castleman disease.
Maithel
Shishir K
SK
Pratt
Wande
W
Kelleher
Thomas
T
Avigan
David
D
Goldman
Harvey
H
Pfeifer
Walther
W
Pihan
German A
GA
Vollmer
Charles M
CM
D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D058846:Antibodies, Monoclonal, Murine-Derived; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D001707:Biopsy, Needle; D005871:Castleman Disease / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D010195:Pancreatitis / Q000188:drug therapy / Q000209:etiology* / Q000473:pathology; D011241:Prednisone / Q000627:therapeutic use; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D005938:Glucocorticoids; D007155:Immunologic Factors; D000069283:Rituximab; D011241:Prednisone